Free Trial
→ Prepare for the “Mar-a-Lago Accord” Money Shock (From Stansberry Research) (Ad)tc pixel Free RDHL Stock Alerts

Redhill Biopharma (RDHL) SEC Filings & 10K Form

Redhill Biopharma logo
$1.70 +0.00 (+0.01%)
Closing price 03:55 PM Eastern
Extended Trading
$1.68 -0.02 (-0.89%)
As of 05:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare

Recent Redhill Biopharma SEC Filings

Export to Excel
DateFilerForm TypeView
09/09/2025
11:15 PM		Redhill Biopharma (Filer)
Form EFFECT
09/09/2025
11:15 PM		Redhill Biopharma (Filer)
Form EFFECT
09/05/2025
6:06 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/20/2025
8:01 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/18/2025
8:03 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/14/2025
6:00 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/21/2025
8:02 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/02/2025
11:15 PM		Redhill Biopharma (Filer)
Form EFFECT
07/01/2025
11:02 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/25/2025
4:24 PM		Redhill Biopharma (Filer)
Form F-1
Registration statement for securities of certain foreign private issuers  
06/25/2025
4:04 PM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/27/2025
6:00 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/13/2025
6:04 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/05/2025
7:04 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/02/2025
6:01 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/28/2025
6:05 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/17/2025
3:06 PM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/16/2025
6:02 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/10/2025
6:51 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/10/2025
6:36 AM		Redhill Biopharma (Filer)
Form 20-F
Registration statement / Annual report / Transition report  
04/08/2025
6:00 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/26/2025
6:00 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/18/2025
6:02 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/12/2025
6:01 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/27/2025
6:01 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/25/2025
6:04 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/04/2025
6:04 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/03/2025
3:28 PM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/03/2025
3:05 PM		Redhill Biopharma (Filer)
Form 424B5
01/21/2025
6:05 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/10/2024
6:03 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/02/2024
6:03 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/14/2024
11:22 AM		CVI Investments, Inc. (Filed by)
Redhill Biopharma (Subject)
Form SC 13G/A
10/28/2024
6:01 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/22/2024
6:01 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/15/2024
5:02 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/01/2024
6:02 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/30/2024
6:01 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/18/2024
8:00 AM		Redhill Biopharma (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
(Data available from 1/1/2016 forward)


Related Companies and Tools

Related Companies
SEC Filings Tools

This page (NASDAQ:RDHL) was last updated on 9/18/2025 by MarketBeat.com Staff
From Our Partners
REVEALED: Something Big Happening Behind White House Doors
what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...
Paradigm Press | Sponsoredtc pixel
Crypto Gets Official Government Backing—Here's the Winner
Trump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...
Crypto 101 Media | Sponsoredtc pixel
An $8 trillion-dollar discovery 17,000 ft underwater
A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...
Porter & Company | Sponsoredtc pixel
Nvidia CEO Makes First Ever Tesla Announcement
While headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...
Brownstone Research | Sponsoredtc pixel
Forget NVDA. Put $1,000 into this stock now
A massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...
Chaikin Analytics | Sponsoredtc pixel
Capital Gains Tax Strategies for Seniors
Capital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...
SmartAsset | Sponsoredtc pixel
October 28–29: The Sequel to Powell’s 0.25% Rate Shock
The Fed just cut rates — and Wall Street insiders are already repositioning. While Powell’s 0.25% move may loo...
American Alternative | Sponsoredtc pixel
Recession Risk: 90% — Are Your Savings Ready?
Moody's latest report shows one-third of U.S. economic activity is already in recession or at high risk.
Lear Capital | Sponsoredtc pixel